ICIs that target PD-1/PD-L1 axis, in particular, have been utilized to treat different types of cancer, however; the response rate among treated patients remains rather modest with CRC being at the lower of the spectrum (52, 53). This evidence concerns the gene PDCD1 and colorectal carcinoma.